Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

7 Day Ceasefire Iran Offer, Trump-Xi AI Rivalry, More 10 min · 25 Sep 2026 · Bloomberg News Now

#685 - Joey Diaz 1h 59m · 25 Sep 2026 · This Past Weekend w/ Theo Von

NPR News: 09-25-2026 1AM EDT 5 min · 25 Sep 2026 · NPR News Now

1AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Same Yesterday, Today, and Forever 6 min · 25 Sep 2026 · Things Unseen with Sinclair B. Ferguson

The killer driver and member of Cock-Wall gang who poured bleach on elderly woman 22 min · 25 Sep 2026 · Crime World

Report any issue

Source

Recorded28 Oct 2025

Publisherc.answersincme.com ↗

Handlerec:10322483

Show notes

Please visit answersincme.com/ZMN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses first-line treatment of advanced EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Review current guideline recommendations for the first-line treatment of advanced EGFR-mutated NSCLC; Describe the clinical implications of the latest evidence on first-line therapeutic strategies for advanced EGFR-mutated NSCLC; and Outline evidence-based strategies to personalize first-line therapeutic selection for patients with advanced EGFR-mutated NSCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in